FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula [I-D1] or pharmaceutically acceptable salt thereof,
,
where each symbol is defined in the claim. The invention also relates to pharmaceutical compositions containing said compound and having HCV polymerase inhibiting activity.
EFFECT: disclosed compound exhibits anti-HCV activity, based on HCV polymerase inhibiting activity and is useful as an agent for preventing and treating hepatitis C.
32 cl, 497 tbl, 1129 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INDOLE DERIVATIVE | 2007 |
|
RU2454415C9 |
| NOVEL PHENYL PYRROLE DERIVATIVE | 2009 |
|
RU2470917C2 |
| 2,5,7-SUBSTITUTED OXAZOLPYRIMIDINE DERIVATIVES | 2011 |
|
RU2557246C2 |
| HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | 2011 |
|
RU2559896C2 |
| 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | 2011 |
|
RU2554874C2 |
| PREVENTIVE OR THERAPEUTIC REMEDY FOR PHOTODERMATOSIS | 2021 |
|
RU2812785C1 |
| CARBOXYLIC ACID DERIVATIVES CONTAINING 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | 2011 |
|
RU2564018C2 |
| 6-(HETEROCYCLYL-SUBSTITUTED BENZYL)-4-OXOQUINOLINE DERIVATIVE AND USE THEREOF AS HIV INTEGRASE INHIBITOR | 2007 |
|
RU2399616C1 |
| METHOD OF RESIDUAL LIPOPROTEINS PRODUCING INHIBITION | 2004 |
|
RU2330682C2 |
| PYRAZINE DERIVATIVES, USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS | 2006 |
|
RU2417994C2 |
